Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties

Journal of Medicinal Chemistry

Volumn 45, Issue 7, 2002, Pages 1466-1476

  Scozzafava, Andrea ^a   Menabuoni, Luca ^b   Mincione, Francesco ^a,c   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Ospedale San Giovanni di Dio   (Italy)

^c Ospedale di Pescia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETOACETIC ACID DERIVATIVE; ACID ANHYDRIDE; ALUMINUM; ANTIGLAUCOMA AGENT; BRINZOLAMIDE; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; CARBOXYLIC ACID; CATION; COPPER ION; DICLOFENAMIDE; DIGLYCINE; DORZOLAMIDE; EDETIC ACID; EDETIC ACID DERIVATIVE; ETHOXZOLAMIDE; FUNCTIONAL GROUP; METAL COMPLEX; METHAZOLAMIDE; NITRILOTRIACETIC ACID; PENTETIC ACID; PENTETIC ACID DERIVATIVE; POLYAMINE; SULFONAMIDE; UNINDEXED DRUG; WATER; ZINC ION;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; ENZYME INHIBITION; GLAUCOMA; INTRAOCULAR PRESSURE; NONHUMAN; PH; RABBIT; SOLUBILITY;

ANIMALS; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; CHELATING AGENTS; CHLOROFORM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORNEA; DNA, COMPLEMENTARY; EDETIC ACID; ENZYME INHIBITORS; ESCHERICHIA COLI; GLAUCOMA; HUMANS; HYDROGEN-ION CONCENTRATION; IMINO ACIDS; KINETICS; MALE; MODELS, CHEMICAL; NITRILOTRIACETIC ACID; PENTETIC ACID; PRESSURE; RABBITS; SULFONAMIDES; TEMPERATURE; TIME FACTORS; ULTRAVIOLET RAYS; WATER;

EID: 0037187391     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0108202     Document Type: Article

References (51)

1. Carbonic anhydrase inhibitors and their therapeutic potential
2. Carbonic anhydrase inhibitors
3. Carbonic anhydrase inhibitors
4. Carbonic anhydrase inhibition in ophthalmology: Aqueous humor secretion and development of sulphonamide inhibitors
5. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion
6. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors
7. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt)
8. Irreversible corneal decompensation in patients treated with topical dorzolamide
9. Contact allergy to dorzolamide eyedrops
10. Nephrolithiasis with dorzolamide
11. Anorexia, depression and dementia induced by dorzolamide eyedrops (Trusopt)
12. The design of new carbonic anhydrase inhibitors
13. Carbonic anhydrase inhibitors. Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action
14. Carbonic anhydrase inhibitors. Water soluble 4-sulfamoylphenyl-thioureas as topical intraocular pressure lowering agents with long lasting effects
15. 2H-thieno [3,2-e]- and [2,3-e]-1,2-thiazine-6-sulfonamide 1,1-dioxides as ocular hypotensive agents: Synthesis, carbonic anhydrase inhibition and evaluation in the rabbit
16. Carbonic anhydrase inhibitors: Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring?
17. Carbonic anhydrase inhibitors: Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route
18. Carbonic anhydrase inhibitors: Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing 8-quinoline-sulfonyl moieties: Is the tail more important than the ring?
19. Carbonic anhydrase inhibitors: Topical sulfonamide antiglaucoma agents incorporating secondary amine moieties
20. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents?
21. Identification of two hydrophobic patches in the active-site cavity of human carbonic anhydrase II by solution-phase and solid-state studies and their use in the development of tightbinding inhibitors
22. Carbonic anhydrase inhibitors. Sulfonamides incorporating furan-, thiophene-, and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions
23. Carbonic anhydrase inhibitors. Synthesis of sulfonamides incorporating dtpa tails and of their zinc complexes with powerful topical antiglaucoma properties
24. Carbonic anhydrase inhibitors. Part 52. Metal complexes of heterocyclic sulfonamides: A new class of strong topical intraocular pressure-lowering agents with potential use as antiglaucoma drugs
25. Carbonic anhydrase inhibitors. Part 91. Metal complexes of heterocyclic sulfonamides as potential pharmacological agents in the treatment of gastric acid secretion imbalances
26. Antifungal activity of silver and zinc complexes of sulfadrug derivatives incorporating arylsulfonylureido moieties
27. Antifungal activity of Ag(I) and Zn(II) complexes of aminobenzolamide (5-sulfanilylamido-1,3,4-thiadiazole-2-sulfonamide) derivatives
28. Carbonic anhydrase activators. Part 21. Novel activators of isozymes I, II and IV incorporating carboxamido- and ureido histamine moieties
29. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine
30. Activation of carbonic anhydrase isozymes
31. A new reagent for tertbutoxycarbonylation: 2-tert-butoxycarbonyloxyimino-2-phenylacetonitrile
32. Complexes of heterocyclic sulfonamides - A class of dual carbonic anhydrase inhibitors
33. 2O. Carbonic anhydrase inhibitory activity
34. 4 complex
35. Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties
36. Carbonic anhydrase inhibitors. Part 61. Quantum Chemical QSAR of a group of benzenedisulfonamides
37. Structure-function relations in human carbonic anhydrase II as studied by site-directed mutagenesis
38. Fine tuning of the catalytic properties of carbonic anhydrase. Studies of a Thr200-His variant of human isoenzyme II
39. Carbon-13 nuclear magnetic resonance probe of active site ionization of human carbonic anhydrase B
40. The catalytic mechanism of carbonic anhydrase
41. The catalytic mechanism of carbonic anhydrase. Hydrogen-isotope effects on the kinetic parameters of the human C isoenzyme
42. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme
43. The catalytic versatility of erythrocyte carbonic anhydrase. 3. Kinetic studies of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate
44. Catalysis and inhibition of human carbonic anhydrase IV
45. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide
46. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors
47. L-662,- 583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals
48. Carbonic anhydrase inhibitors. Part 29. Interaction of isozymes I, II and IV with benzolamide-like derivatives
49. Topically active ocular carbonic anhydrase inhibitors: Novel biscarbonylamidothiadiazole sulfonamides as ocular hypotensive agents
50. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide - A novel topically active carbonic anhydrase inhibitor